ZARR

News and price dashboard

Swept 14:18
Sources
27, all reachable
Items
57467
Flagged
7334
Last swept
14:18

Sources

All 27 enabled. Mute or unmute any of them.

Show stories from muted sources

STOCKS

120

OPTIONS

25

COMING UP

US majors and your names' earnings, next 7 days

Full calendar

Everything else — unscored, browse only, never pushed

Brief

CoreWeave credit stress dominates the feed

The busiest story here is CoreWeave, covered by two full-text pieces plus a Cantor note. The stock slipped nearly 4.9% in pre-open trade to $66.31 after a week-long confidence shock running through its whole capital structure: yields on its 2031 bonds have climbed toward 16% and credit default swaps briefly topped 1,140 basis points, implying a market-priced default probability above 60% over five years. It was down more than 15% on the week heading into Friday, against a 52-week low of $59.51. Opinion is split. Cantor Fitzgerald's Brett Knoblauch called the selloff "a lot of fearmongering," reiterated Overweight with a $176 target, and noted CoreWeave has public backing from Nvidia, has sold out nearly all 2027 capacity, and has an Nvidia agreement to backstop anything unsold — the worry, he argues, is funding capex, not demand. Bank of America projects roughly $67 billion in cumulative negative free cash flow through 2028 but still expects operating profit to cover interest by that year. Nvidia's Jensen Huang said in Stockholm that "CoreWeave's strength is improving every day," which helped the stock bounce about 6% Thursday. Background noted in the articles: total debt of $51.6 billion, a Gartner warning that most neocloud operators may not survive the decade, an India expansion with AdaniConneX adding 240MW at Navi Mumbai, Evercore ISI at Outperform/$150 and Northland lifting to $200 from $165. Note the page's own ticker widget showed CRWV at $69.69, up 5.94%, so the article's pre-market figure and the live quote point different ways.

Strategy and the MSCI index rule

Strategy fell 3.0% pre-open after MSCI formally approved new eligibility rules late Thursday that classify firms acting more like investment vehicles than operating businesses as "non-operating companies," ineligible for its Global Investable Market Indexes. The framework takes effect at the close of November 30, 2026, and MSCI's own simulation flagged Strategy as likely qualifying. JPMorgan estimates removal could force roughly $2.8 billion of passive selling. Strategy's counter-argument is that MSCI-linked funds hold about 13 million shares, around 3.1% of basic shares outstanding, less than a typical day's volume. The final affected list is due November 11, and existing members must fail the tests across two successive annual reporting periods before removal bites. Bitcoin's October 15 drop below $80,000 after the hot September CPI print added a second headwind, taking MSTR to a pre-market low of $134.89 versus a 52-week high of $306.16. Separately, a headline notes Cantor Fitzgerald raised its Strategy price target on bitcoin gains, and a tweet in the feed puts that new target at $208 from $186 with a $112,000 bitcoin assumption.

Travelers beats and sells off anyway

Travelers slid 4.6% pre-open despite Q3 adjusted EPS of $9.18 against roughly $7.25 expected and revenue of $12.41 billion versus about $11.31 billion. The detail behind the drop: catastrophe losses jumped to $538 million, Personal Insurance segment income fell year over year on those weather costs, revenue was essentially flat year on year, and net income rose only to $1.917 billion from $1.888 billion. The stock went in near its 52-week high after roughly a 46% twelve-month gain, with about 21 brokers at a Hold consensus and Wells Fargo at equal-weight.

Omeros loses its European path

Omeros dropped 5.4% pre-open to $17.77 from a $18.79 close after the EMA's CHMP issued a second negative opinion on narsoplimab, branded Yartemlea, for stem cell transplant-associated thrombotic microangiopathy. This followed a formal re-examination of the June 2026 rejection, which included an eight-member ad hoc panel of hematologists, statisticians, transplant physicians and patient representatives. Omeros will end its European compassionate-use program, citing rising U.S. demand, and said licensing EU rights to a third party is no longer viable. The article also flags about $3 million of net insider selling over twelve months with no purchases. The U.S. launch is unaffected; next earnings are mid-November.

Mobileye and Klaviyo, opposite analyst calls

Two names moved purely on broker action. Mobileye rallied 4.3% pre-open to $7.75 after Citi initiated at Buy with an $11 target, analyst Michael Ward arguing the industry's safety push makes Mobileye a long-term beneficiary after 25 years in ADAS. Morgan Stanley cut its target to $9 from $10 the same morning but stayed Equal Weight; consensus sits near $11.25, and Q3 results land October 29. Klaviyo went the other way, down 2.2%, after Goldman Sachs cut it from Buy to Neutral and the target from $27 to $20. Analyst Callie Valenti cited less confidence in the timing and scale of AI agents, enterprise expansion, international and new channels, plus a more cautious view on SMB software spend. Goldman only initiated at Buy in late June 2026. The downgrade follows Q2 target cuts after non-GAAP gross margin contraction and a lowered operating income outlook, even with revenue up 26% to $370.6 million.

Varonis takeout at $49.75

Cantor Fitzgerald kept Overweight and a $55 target on Varonis after Proofpoint, owned by Thoma Bravo, agreed Tuesday to buy it for about $6.3 billion, or $49.75 a share in cash, unanimously approved by the board. That is roughly a 52% premium to the $32.71 close on June 22, 2026, before take-private rumours; shares trade at $47.34, about 5% below the deal price. The price works out near 53 times trailing free cash flow and 8.4 times trailing revenue on $688 million of revenue at 77% gross margin. Closing is expected in the first half of 2027. Rosenblatt, TD Cowen, DA Davidson, Needham and RBC have all cut to neutral-equivalent ratings at or near the deal price. Q3 results are due November 3.

Macro backdrop referenced across the articles

Several of the full-text pieces lean on the same macro facts: September U.S. CPI at 3.7% year over year versus 3.4% prior, a hotter-than-expected wholesale inflation print the prior session, renewed talk of further Fed hikes, and the Philadelphia Semiconductor Index shedding about 12% over six sessions through mid-week, around $1.6 trillion of sector value. Headline-only items in the same vein include BofA warning the AI boom shows classic capital-cycle risk, Fed's Warsh saying AI could boost growth but warning of a bumpy transition while avoiding rate guidance, and a Nasdaq close higher as a bond rally offset tech softness.

Eni earnings-move implied by options

One short full-text piece: options data compiled by Bloomberg implies a 1.1% move in Eni shares around its October 23 pre-open earnings. The article's point is that Eni has exceeded the implied move in seven of the last eight reports — a 2.7% implied versus 7.8% actual on July 29, 0.5% implied versus 7.2% on October 24, 2025, and so on, with February 27, 2025 the only undershoot.

Headline-only broker and corporate flow

A thick layer of broker notes, read only as headlines. Needham initiated a retail batch: Boot Barn and Urban Outfitters at Buy on growth potential, Victoria's Secret at Buy with a $106 target, Gap at Hold on mixed brand performance, Kontoor Brands at Hold. Elsewhere Cantor raised Procore to $70 and lifted Bentley Systems on infrastructure demand; Stifel reiterated Glaukos, Crescent Biopharma and Valmont (Buy, $678), cut Semtech to $200 on valuation and raised Chatham Lodging on AI tailwinds; Morgan Stanley raised Semtech on data centre growth; DA Davidson upgraded Martin Marietta to buy; Goldman downgraded GVS saying the rally leaves limited upside, and flagged two memory stocks to buy into the sector pullback; H.C. Wainwright reiterated Halozyme on Takeda trial data and initiated Eikon Therapeutics at Buy; Wedbush's Dan Ives kept his GameStop rating on the collectibles shift. Corporate headlines: Fox Factory named an interim CEO and cut its fiscal 2026 outlook, Shell is reported to be selling its French mobility business to DCC Energy, NiSource signed a power deal with Microsoft for an Indiana campus, Lockheed delivered a C-130J for a Navy nuclear command mission, Royalty Pharma declared a $0.235 Q4 dividend payable December 10, and Besi fell on a report ASML is developing a competing hybrid bonding product.

Indian earnings cluster

A run of Indian results slides and transcripts, headline-only: South Indian Bank and Federal Bank both posting record quarterly profit, Federal Bank with what it calls decadal-low NPAs; E2E Networks with revenue up 411% on GPU expansion and surging results on AI demand; Aurum PropTech profitable as the Housing.com deal closes; Metro Brands past 1,000 stores with profit beating estimates; 5paisa profit down 39% as tech spending weighs on margins; and D.B. Corp beating on revenue.

Filings and technical chatter

The rest is low-signal. Form 144 filings for Medtronic, CarGurus and Plug Power appear as full-text items but contain no content beyond the filing notice itself, and there are routine Form 4 and DEF 14A items for Meta, Actinium, ASP Isotopes and others, plus Albion Crown VCT share conversions and a PHSC chair stepping down. A large share of the 200 items are TradingView chart posts on gold, bitcoin, ETH, XRP, NASDAQ and various FX pairs, which are individual traders' setups rather than news.

20 read in full, 200 items in the section

Feed

149 stories · 149 newCross-publisher stories only